Literature DB >> 1618740

Comparison of two reconstituted systems for in vitro transcription and replication of influenza virus.

B L Seong1, M Kobayashi, K Nagata, G G Brownlee, A Ishihama.   

Abstract

The transcription and replication of influenza RNA can be studied in vitro by the reconstitution of functional ribonucleoprotein (RNP) complex from viral core proteins including the RNA polymerase (complex of three P protein subunits) and nucleoprotein (NP), and model templates. Here, two different core protein preparations, one based on CsCl centrifugation (CS enzyme) and the other on micrococcal nuclease treatment of viral cores (MN enzyme), were compared side-by-side. Short model RNA templates and their 3'-half molecules of both viral RNA (vRNA) and complementary RNA (cRNA) senses were reconstituted with the core protein preparations in parallel, and RNA polymerase activity was tested either in the presence or absence of ApG or globin mRNA as primers. Both enzyme preparations were active in the syntheses of short vRNA and cRNA transcripts using ApG as a primer, although the synthesis of cRNA was 2-10-fold higher (depending on the template used) than the synthesis of vRNA. The MN enzyme, however, was more active per weight of total protein than the CS enzyme, probably because of its higher content of RNA polymerase. Both enzymes failed to show primer-independent synthesis of vRNA. The differences observed in the synthesis of short transcripts using globin mRNA as a primer are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618740     DOI: 10.1093/oxfordjournals.jbchem.a123786

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  12 in total

1.  Cellular splicing factor RAF-2p48/NPI-5/BAT1/UAP56 interacts with the influenza virus nucleoprotein and enhances viral RNA synthesis.

Authors:  F Momose; C F Basler; R E O'Neill; A Iwamatsu; P Palese; K Nagata
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  The RNA polymerase of influenza virus, bound to the 5' end of virion RNA, acts in cis to polyadenylate mRNA.

Authors:  L L Poon; D C Pritlove; J Sharps; G G Brownlee
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  A hairpin loop at the 5' end of influenza A virus virion RNA is required for synthesis of poly(A)+ mRNA in vitro.

Authors:  D C Pritlove; L L Poon; L J Devenish; M B Leahy; G G Brownlee
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

4.  Polyadenylation of influenza virus mRNA transcribed in vitro from model virion RNA templates: requirement for 5' conserved sequences.

Authors:  D C Pritlove; L L Poon; E Fodor; J Sharps; G G Brownlee
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Molecular dissection of influenza virus RNA polymerase: PB1 subunit alone is able to catalyze RNA synthesis.

Authors:  T Toyoda; M Kobayashi; S Nakada; A Ishihama
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

6.  The influenza virus panhandle is involved in the initiation of transcription.

Authors:  E Fodor; D C Pritlove; G G Brownlee
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Influenza virus PB1 protein is the minimal and essential subunit of RNA polymerase.

Authors:  M Kobayashi; T Toyoda; A Ishihama
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

8.  Mechanism for inhibition of influenza virus RNA polymerase activity by matrix protein.

Authors:  K Watanabe; H Handa; K Mizumoto; K Nagata
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Characterization of the RNA-fork model of virion RNA in the initiation of transcription in influenza A virus.

Authors:  E Fodor; D C Pritlove; G G Brownlee
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Polycistronic Expression of the Influenza A Virus RNA-Dependent RNA Polymerase by Using the Thosea asigna Virus 2A-Like Self-Processing Sequence.

Authors:  Fumitaka Momose; Yuko Morikawa
Journal:  Front Microbiol       Date:  2016-03-08       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.